NLRX1 mitigates tumorigenesis in a genetic model of sporadic colon cancer, APCmin/+
Nlrx1−/− colons have increased activation of tumor inducing STAT3, NFκB, MAPK, and IL6
Anti-IL6R therapy reduces mortality and tumor development in Nlrx1−/−APCmin/+ mice
Human colon tumors exhibit significantly lower levels of NLRX1 in multiple datasets